Your browser doesn't support javascript.
loading
The 2016 WHO versus 2008 WHO Criteria for the Diagnosis of Chronic Myelomonocytic Leukemia.
Moon, Yeonsook; Kim, Mi Hyang; Kim, Hye Ryoun; Ahn, Jeong Yeal; Huh, Jungwon; Huh, Ji Young; Han, Jae Ho; Park, Joon Seong; Cho, Sung Ran.
Afiliación
  • Moon Y; Department of Laboratory Medicine, Inha University School of Medicine, Incheon, Korea.
  • Kim MH; Department of Laboratory Medicine, Kosin University College of Medicine, Busan, Korea.
  • Kim HR; Department of Laboratory Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
  • Ahn JY; Department of Laboratory Medicine, Gachon University Gil Hospital, Incheon, Korea.
  • Huh J; Department of Laboratory Medicine, College of Medicine, Ewha Womans University, Seoul, Korea.
  • Huh JY; Department of Laboratory Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
  • Han JH; Department of Pathology, Ajou University School of Medicine, Suwon, Korea.
  • Park JS; Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea.
  • Cho SR; Department of Laboratory Medicine, Ajou University School of Medicine, Suwon, Korea. sungran@aumc.ac.kr.
Ann Lab Med ; 38(5): 481-483, 2018 Sep.
Article en En | MEDLINE | ID: mdl-29797820
ABSTRACT
The 2016 WHO diagnostic criteria for chronic myelomonocytic leukemia (CMML) require both absolute and relative monocytosis (≥1×109/L and ≥10% of white blood cell counts) in peripheral blood. Moreover, myeloproliferative neoplasm (MPN) features in bone marrow and/or MPN-associated mutations tend to support MPN with monocytosis rather than CMML. We assessed the impact of the 2016 WHO criteria on CMML diagnosis, compared with the 2008 WHO criteria, through a retrospective review of the medical records of 38 CMML patients diagnosed according to the 2008 WHO classification. Application of the 2016 WHO criteria resulted in the exclusion of three (8%) patients who did not fulfill the relative monocytosis criterion and eight (21%) patients with an MPN-associated mutation. These 11 patients formed the 2016 WHO others group; the remaining 27 formed the 2016 WHO CMML group. The significant difference in the platelet count and monocyte percentage between the two groups indicated that the 2016 WHO criteria lead to a more homogenous and improved definition of CMML compared with the 2008 WHO criteria, which may have led to over-diagnosis of CMML. More widespread use of molecular tests and more sophisticated clinical and morphological evaluations are necessary to diagnose CMML accurately.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Leucemia Mielomonocítica Crónica Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies Idioma: En Revista: Ann Lab Med Año: 2018 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Leucemia Mielomonocítica Crónica Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies Idioma: En Revista: Ann Lab Med Año: 2018 Tipo del documento: Article